Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin

Biomaterials

Volumn 35, Issue 6, 2014, Pages 2032-2038

  Khara, Jasmeet S ^a   Wang, Ying ^a   Ke, Xi Yu ^b   Liu, Shaoqiong ^b   Newton, Sandra M ^c   Langford, Paul R ^c   Yang, Yi Yan ^b   Ee, Pui Lai Rachel ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antimicrobial peptides; Drug resistance; Mycobacterium tuberculosis; Synergy; Helical

Indexed keywords

AMINO ACIDS; BACTERIA; HYDROPHOBICITY; TUBES (COMPONENTS);

ANTIMICROBIAL PEPTIDE; DRUG RESISTANCE; DRUG-RESISTANT BACTERIA; HYDROPHOBIC AMINO ACIDS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; SYNERGISTIC COMBINATIONS; SYNERGY;

PEPTIDES;

AMINO ACID; BCG VACCINE; CATIONIC ALPHA HELICAL PEPTIDE; CYSTEINE; METHIONINE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; THIOL GROUP; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; HYDROPHOBICITY; LETHAL DOSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

CORYNEBACTERINEAE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS;

ANTIMICROBIAL PEPTIDES; DRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; SYNERGY; Α-HELICAL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PEPTIDES; RIFAMPIN;

EID: 84890140255     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.035     Document Type: Article

References (40)

1. WHO Global tuberculosis report 2012 2012, World Health Organization, Geneva.
2. WHO Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response 2010, World Health Organization, Geneva.
3. Wong E.B., Cohen K.A., Bishai W.R. Rising to the challenge: new therapies for tuberculosis. Trends Microbiol 2013, 21:493-501.
4. Fox J.L. Antimicrobial peptides stage a comeback. Nat Biotechnol 2013, 31:379-382.
5. Hancock R.E., Sahl H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006, 24:1551-1557.
6. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1999, 1462:10.
7. Yang L., Weiss T.M., Lehrer R.I., Huang H.W. Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys J 2000, 79:2002-2009.
8. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999, 1462:55-70.
9. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
10. Fattorini L., Gennaro R., Zanetti M., Tan D., Brunori L., Giannoni F., et al. Invitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Peptides 2004, 25:1075-1077.
11. Jiang Z., Higgins M.P., Whitehurst J., Kisich K.O., Voskuil M.I., Hodges R.S. Anti-tuberculosis activity of α-helical antimicrobial peptides: de novo designed L-and D-Enantiomers versus L-and D-LL37. Protein Pept Lett 2011, 18:241-252.
12. Kisich K.O., Higgins M., Diamond G., Heifets L. Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun 2002, 70:4591-4599.
13. Linde C.M., Hoffner S.E., Refai E., Andersson M. Invitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis. JAntimicrob Chemother 2001, 47:575-580.
14. Miyakawa Y., Ratnakar P., Rao A.G., Costello M.L., Mathieu-Costello O., Lehrer R.I., et al. Invitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect Immun 1996, 64:926-932.
15. Sharma S., Verma I., Khuller G. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: invitro and exvivo study. Eur Respir J 2000, 16:112-117.
16. Bell G., Gouyon P.-H. Arming the enemy: the evolution of resistance to self-proteins. Microbiology 2003, 149:1367-1375.
17. Loose C., Jensen K., Rigoutsos I., Stephanopoulos G. Alinguistic model for the rational design of antimicrobial peptides. Nature 2006, 443:867-869.
18. Wiradharma N., Khoe U., Hauser C.A., Seow S.V., Zhang S., Yang Y.-Y. Synthetic cationic amphiphilic α-helical peptides as antimicrobial agents. Biomaterials 2011, 32:2204-2212.
19. Wiradharma N., Khan M., Yong L.-K., Hauser C.A., Seow S.V., Zhang S., et al. The effect of thiol functional group incorporation into cationic helical peptides on antimicrobial activities and spectra. Biomaterials 2011, 32:9100-9108.
20. Ramón-García S., Mikut R., Ng C., Ruden S., Volkmer R., Reischl M., et al. Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother 2013, 57:2295-2303.
21. Rivas-Santiago B., Rivas Santiago C.E., Castaneda-Delgado J.E., Leon-Contreras J.C., Hancock R.E., Hernandez-Pando R. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents 2013, 41:143-148.
22. Snewin V.A.G.M., Gaora P.O., Hasan Z., Brown I.N., Young D.B. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 1999, 67:4586-4593.
23. Liu L., Xu K., Wang H., Tan P.J., Fan W., Venkatraman S.S., et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 2009, 4:457-463.
24. Wang H., Xu K., Liu L., Tan J.P., Chen Y., Li Y., et al. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials 2010, 31:2874-2881.
25. Rand K., Houck H., Brown P., Bennett D. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother 1993, 37:613-615.
26. Jacobs D.S., DeMott W.R., Oxley D.K. Jacobs & DeMott laboratory test handbook with key word index 2001, Lexi Comp, Hudson, OH. 5th ed.
27. Eliopoulos G.M., Moellering R.C. Antibiotic combinations 1991, The Williams & Wilkins Co., Baltimore, MD. 3rd ed.
28. Dathe M., Schümann M., Wieprecht T., Winkler A., Beyermann M., Krause E., et al. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 1996, 35:12612-12622.
29. Lee D.G., Kim H.N., Park Y., Kim H.K., Choi B.H., Choi C.-H., et al. Design of novel analogue peptides with potent antibiotic activity based on the antimicrobial peptide, HP (2-20), derived from N-terminus of Helicobacter pylori ribosomal protein L1. Biochim Biophys Acta 2002, 1598:185-194.
30. Estieu-Gionnet K., Guichard G. Stabilized helical peptides: overview of the technologies and therapeutic promises. Expert Opin Drug Discov 2011, 6:937-963.
31. Chen Y., Mant C., Farmer S., Hancock R., Vasil M., Hodges R. Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. JBiol Chem 2005, 280:12316-12329.
32. Chen Y., Guarnieri M.T., Vasil A.I., Vasil M.L., Mant C.T., Hodges R.S. Role of peptide hydrophobicity in the mechanism of action of a-helical antimicrobial peptides. Antimicrob Agents Chemother 2007, 51:1398-1406.
33. Guerrero E., Saugar JMa, Matsuzaki K., Rivas L. Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob Agents Chemother 2004, 48:2980-2986.
34. Ramaswamy S., Musser M.J. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998, 79:3-29.
35. NCCLS Methods for determining bactericidal activity of antimicrobial agents; approved guideline 1999, NCCLS, Wayne, Pennsylvania, USA.
36. Sader H.S., Fedler K.A., Rennie R.P., Stevens S., Jones R.N. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 2004, 48:3112-3118.
37. Maisetta G., Batoni G., Esin S., Florio W., Bottai D., Favilli F., et al. Invitro bactericidal activity of human β-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob Agents Chemother 2006, 50:806-809.
38. Anantharaman A., Rizvi M.S., Sahal D. Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. Antimicrob Agents Chemother 2010, 54:1693-1699.
39. Cirioni O., Silvestri C., Ghiselli R., Orlando F., Riva A., Mocchegiani F., et al. Protective effects of the combination of α-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. JAntimicrob Chemother 2008, 62:1332-1338.
40. Mangoni M.L., Rinaldi A.C., Di Giulio A., Mignogna G., Bozzi A., Barra D., et al. Structure-function relationships of temporins, small antimicrobial peptides from amphibian skin. Eur J Biochem 2000, 267:1447-1454.